Comparative Pharmacology
Head-to-head clinical analysis: CEPHAPIRIN SODIUM versus PENTACEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEPHAPIRIN SODIUM versus PENTACEF.
CEPHAPIRIN SODIUM vs PENTACEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cephapirin sodium is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), primarily PBP1 and PBP3, thereby inhibiting transpeptidation and disrupting peptidoglycan cross-linking, leading to cell lysis mediated by autolytic enzymes.
Cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
500 mg to 1 g IM or IV every 6 hours.
1-2 g IV/IM every 8-12 hours; maximum 6 g/day.
None Documented
None Documented
0.5-1.0 hours; prolonged to 2-5 hours in renal impairment, requiring dose adjustment.
Terminal elimination half-life is 1.5-2 hours; prolonged to 3-5 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 10-20 hours in severe impairment (CrCl <10 mL/min); dosing adjustment required for CrCl <50 mL/min.
Renal: 80-90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <5%.
Approximately 80-90% renal excretion as unchanged drug via glomerular filtration and tubular secretion; 10-20% biliary/fecal elimination.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic